Trial Information
Pharmacogenetics of Gemtuzumab Ozogamicin (GO) Therapy in Acute Myeloid Leukemia
OBJECTIVES:
- To genotype the genomic DNA from acute myeloid leukemia (AML) patients treated on
COG-AAML0531 clinical trial for CD33 (and PgP and SOC3) single nucleotide polymorphisms
(SNPs).
OUTLINE: Archived DNA samples are analyzed for single nucleotide polymorphisms in CD33, PgP,
and SOC3 genes by Sequenome platform. Results are then compared with patients clinical
outcomes, including minimal-residual disease levels post induction I (chemotherapy and
gemtuzumab ozogamicin), complete remission rates, refractory disease with various levels of
bone marrow blasts, development of CNS/persistent disease, event-free survival, overall
survival, and toxicity.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Diagnosed with acute myeloid leukemia
- DNA samples from patients treated on COG-AAML0531
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Genetic changes in CD33 impact outcome of gemtuzumab ozogamicin-based therapy
Safety Issue:
No
Principal Investigator
Jatinder Lamba, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Masonic Cancer Center, University of Minnesota
Authority:
United States: Federal Government
Study ID:
CDR0000706823
NCT ID:
NCT01407757
Start Date:
July 2011
Completion Date:
Related Keywords:
- Leukemia
- adult acute myeloid leukemia with 11q23 (MLL) abnormalities
- adult acute myeloid leukemia with del(5q)
- adult acute myeloid leukemia with inv(16)(p13;q22)
- adult acute myeloid leukemia with t(16;16)(p13;q22)
- adult acute myeloid leukemia with t(8;21)(q22;q22)
- untreated adult acute myeloid leukemia
- untreated childhood acute myeloid leukemia and other myeloid malignancies
- adult acute basophilic leukemia
- childhood acute basophilic leukemia
- adult acute eosinophilic leukemia
- childhood acute eosinophilic leukemia
- adult acute myeloblastic leukemia without maturation (M1)
- childhood acute myeloblastic leukemia without maturation (M1)
- adult acute minimally differentiated myeloid leukemia (M0)
- childhood acute minimally differentiated myeloid leukemia (M0)
- adult acute myeloblastic leukemia with maturation (M2)
- childhood acute myeloblastic leukemia with maturation (M2)
- adult acute myelomonocytic leukemia (M4)
- childhood acute myelomonocytic leukemia (M4)
- adult acute monoblastic leukemia (M5a)
- adult acute monocytic leukemia (M5b)
- childhood acute monoblastic leukemia (M5a)
- childhood acute monocytic leukemia (M5b)
- adult erythroleukemia (M6a)
- adult pure erythroid leukemia (M6b)
- childhood acute erythroleukemia (M6)
- adult acute megakaryoblastic leukemia (M7)
- childhood acute megakaryocytic leukemia (M7)
- recurrent adult acute myeloid leukemia
- recurrent childhood acute myeloid leukemia
- Leukemia
- Leukemia, Myeloid, Acute
- Leukemia, Myeloid